Rodman & Renshaw initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $17 price target citing the company’s “differentiated” at-home agitation franchise, expanding BXCL501 neuropsychiatry options, and what it calls “an extreme disconnect between enterprise value and risk-adjusted cash flow potential.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics Announces Registered Direct Equity Financing
- BioXcel price target lowered to $6 from $10 at H.C. Wainwright
- BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
- BTAI Upcoming Earnings Report: What to Expect?
- BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia